Fig. 2
From: Fc-engineered monoclonal antibodies to reduce off-target liver uptake
Anti-AXL D4a IgG with LALAPG Fc displays lower liver retention than the IgG with WT Fc. A Maximal Intensity Projection PET images of mice subcutaneously xenografted with myoblasts (left flank) and tumor cells (right flank; CFPAC-1 cells for the IgG with WT Fc and MDA-MB-231 cells for the IgG with LALAPG Fc) at 48, 72 and 96 h after injection of 89Zr-radioimmunolabeled anti-AXL D4a IgG with LALAPG Fc or WT Fc (n = 3 mice per group). The low and high values correspond to 1 and 5% AI/g respectively and are indicated by a low and high line on the scale. B Quantitative PET analysis of anti-AXL IgG in liver at 48 h, 72 h and 96 h post-injection, expressed in %IA/cm3. C Conventional biodistribution analysis of the anti-AXL IgG in liver and tumors (CFPAC-1 cells for the IgG with WT Fc and MDA-MB-231 cells for the IgG with LALAPG Fc) at 96 h post-injection. The percentage of activity in the organ (%IA/g) corresponds to the injected activity related to the organ weight. For panels B and C: *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001; ns, not significant (unpaired two-tailed t test)